Abcodia, VolitionRx Collaborate on Nucleosome-based Dx for Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.

The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.